Please assess the completion status of the following clinical trial:

Trial Title: Vorapaxar in the Human Endotoxemia Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~  * ≥60 kg bodyweight~ * Normal findings in medical history and physical examination unless the investigator considers the abnormality to be clinically irrelevant~ * Normal laboratory values unless the investigator considers abnormalities to be clinically irrelevant~ * Willingness to comply with the trial's safety demands (to refrain from excessive sporting activities two weeks after Vorapaxar intake, i.e. full contact sports, climbing, mountain biking etc.)~ * Ability to understand the purpose and nature of the study, as well as the associated risks No planned surgeries or other medical interventions in the planned study period~Exclusion Criteria:~* Intake of any drugs that may interfere with the trial's endpoints or drugs (i.e. platelet inhibitors, anticoagulants, CYP3A4 inhibitors, NSAIDs, selective serotonin reuptake inhibitors, selective noradrenaline and serotonin reuptake inhibitors)~  * Positive results of HIV or hepatitis virology~ * Acute illness with systemic inflammatory reactions~ * Known allergies, hypersensitivities or intolerances to any of the used substances~ * Acute or recent bleeding episodes, increased risk of bleeding at the discretion of the investigator~ * History of stroke, transient ischemic attacks or intracerebral hemorrhage~ * Known coagulation or platelet disorders~ * Participation in an LPS trial within 6 weeks of the first study day~ * Severe liver or kidney dysfunction~ * Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Vorapaxar (Type: EXPERIMENTAL): subjects will be treated with 4x2,5mg vorapaxar in empty lactose-starch capsules
- Placebo (Type: PLACEBO_COMPARATOR): subjects will be treated with 4 empty lactose-starch capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).